# SEQOVA

> Where Innovation Begins


## Posts

- [Bridging NMPA to FDA and EMA: What It Actually Takes to Move a China-Approved Asset West](https://seqova.com/nmpa-fda-ema-bridging-china-pharma-assets/): BD teams evaluating China-origin assets understand that NMPA approval is not FDA or EMA approval. What gets underestimated, consistently, is how much work sits between the two. It’s operational, documented, and expensive. Getting it wrong at term sheet stage means inheriting a program that will cost twice what the model said and take years longer than the timeline projected. Why the Gap Exists China joined ICH in June 2017 and has formally adopted 59 of 63 ICH guidelines, including Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System). On paper, the regulatory alignment is real and has been […]
- [What the EU's Critical Medicines Act Actually Means for Pharma BD Teams](https://seqova.com/eu-critical-medicines-act-pharma-bd-teams/): In May 2026, the European Parliament and Council reached provisional agreement on the Critical Medicines Act. Most of the coverage treated it as a supply chain story. It is also a business development story, and the companies that read it that way will be in a materially better position by 2027. The List Is Already There The Union List of Critical Medicines identifies over 200 active substances where the EU has formally determined that supply continuity is a priority concern. The list has been public since 2023. What the Act does is give it legislative teeth: member states will be required […]
- [How China-Origin Assets Actually Reach EU and US Markets: What the Deal Data Shows](https://seqova.com/china-origin-assets-eu-us-markets-deal-data/): Something shifted in China-to-West licensing between 2024 and 2025, and the numbers are stark enough to be worth taking seriously. In H1 2025, US and European companies signed 14 licensing agreements for Chinese assets worth up to $18.3 billion. In H1 2024, that number was two deals. Every large-cap pharmaceutical company has now sourced from China. The question that matters for everyone below that tier is what this actually means for how deals are structured, priced, and closed. The Bargain Era Is Over The first thing the data shows clearly is that the window of opportunistic pricing has closed. Average upfront […]
- [Why China's Second- and Third-Tier Biotech Companies Represent Europe's Most Undervalued In-Licensing Opportunity](https://seqova.com/china-second-third-tier-biotech-in-licensing-europe/)
- [Beyond Autologous: Why China’s Allogeneic CAR-T Pipeline Deserves European Attention Now](https://seqova.com/beyond-autologous-why-chinas-allogeneic-car-t-pipeline-deserves-european-attention-now/): SEQOVA Biotech Insights | May 2026 The approved CAR-T therapies that reshaped haematological oncology over the past decade were all made from the patient’s own cells. Autologous production is what made the clinical results possible. It is also what makes the therapy structurally difficult to scale, expensive to deliver, and inaccessible to patients who deteriorate before their cells can be processed. The solution — manufacturing CAR-T products from donor cells — has been understood for years. Executing it consistently, safely, and at commercial scale has proved harder. That challenge is now being addressed with increasing sophistication in China, at a pace […]
- [Why Good Assets Don’t Close: The Hidden Weight of Execution](https://seqova.com/why-good-biotech-assets-dont-close-execution-risk-2026/): You can usually tell where a deal is going to get difficult. Not at the beginning. That part usually moves pretty fast. The data looks solid, the positioning makes sense, and there’s enough alignment to justify pushing forward. On the surface, everything lines up. The trouble shows up later. It happens the moment the conversation shifts from what the asset is to how it actually has to be developed, manufactured, and approved across regions. That’s when the real shape of the opportunity starts to reveal itself. And it’s not always as clean as it first looked. In 2026 this pattern has […]
- [Radiopharmaceuticals 2025–2026: Why Cost, Infrastructure, and Workflow Now Matter More Than Novelty](https://seqova.com/radiopharmaceutical-innovation-2026/): Radiopharmaceuticals innovation in 2026 have moved decisively beyond their historical niche in nuclear medicine. What was once a specialised diagnostic adjunct has become a central pillar of precision oncology, driven by the convergence of targeted vectors, radioactive isotopes, and increasingly sophisticated clinical protocols. Yet as the field enters its next phase of growth, the industry’s primary constraint is no longer scientific validation. It is practical adoption. The defining question for radiopharmaceuticals is shifting from “Does it work?” to “Can healthcare systems realistically deploy it at scale?” From Scientific Breakthroughs to System-Level Reality The past five years delivered undeniable momentum:strong clinical data, […]
- [LAI Licensing in Central Nervous System Disorders: Where Execution Risk Sits in 2026](https://seqova.com/cns-lai-licensing-execution-risk-2026/): Interest in long-acting injectables (LAIs) for Central Nervous System (CNS) disorders has returned to business development and investment discussions for a reason, but not the one most people assume. This is not a rediscovery of CNS innovation.It is a reassessment of execution risk. In schizophrenia and bipolar disorder, LAIs are increasingly evaluated as assets that can stabilize portfolios, extend lifecycle value, and reduce commercial volatility. Yet many licensing discussions still stall late in diligence. Not because the molecule is questioned, but because execution assumptions fail to hold under scrutiny. Why CNS LAIs are being revisited Three structural forces are shaping how […]
- [Inhalation Drug Licensing in 2026: Why Execution-Ready Assets Are Queitly Winning](https://seqova.com/inhalation-drug-licensing-2026/): For years, inhalation drug licensing has been misunderstood. It wasn’t deprioritized because it failed scientifically. It was deprioritized because the market rewarded novelty over execution. Biologics, gene therapies, and platform narratives dominated buyers’ attention, while inhaled programs, proven, regulated, and manufacturable, were seen as unexciting. In 2026, that bias is being corrected. Not because inhalation has changed, but because the licensing market has. As buyers face tighter capital discipline, internal execution constraints, and growing lifecycle gaps, the value of clarity, speed, and integration readiness has risen sharply. In that environment, inhalation drug licensing is re-emerging as a strategically efficient way to […]
- [Computerized System Validation (CSV) in Pharma: 2025 Updates and Preparing for 2026 Compliance](https://seqova.com/computerized-system-validation-pharma-2025-2026/): Computerized System Validation (CSV) is no longer a static compliance exercise. In 2025, regulators made that clear. Both the EMA and FDA introduced major updates that reshape how pharmaceutical and biotech companies must approach validation. The focus has shifted. Risk-based thinking, lifecycle management, data integrity, and system security are now front and center. As we move into 2026, organizations that fail to adapt risk falling behind operationally and regulatorily. Key CSV Regulatory Milestones in 2025 EMA Draft Annex 11 (July 2025) The EMA released a substantially expanded draft of Annex 11 – Computerised Systems.The document grew from 9 pages to 19. […]
- [AI in Biotech Manufacturing: Where Value Is Real and Where GMP Caution Is Essential](https://seqova.com/ai-biotech-manufacturing-gmp-2025/): AI Has Moved From Experiment to Infrastructure In 2025, artificial intelligence (AI) is no longer confined to innovation labs or pilot projects in biotech manufacturing. It is increasingly embedded in core operational workflows, from process optimisation and predictive maintenance to quality monitoring and supply resilience. This shift has not gone unnoticed by regulators. In July 2025, the European Medicines Agency (EMA) released a draft Annex 22 on Artificial Intelligence, signalling formal GMP expectations for AI-enabled systems. Earlier in the year, the FDA published draft guidance outlining how AI may support regulatory decision-making across the drug lifecycle, including manufacturing. The message from […]
- [Building Bridges, Not Just Deals: How SEQOVA Cross-Border Partnerships Are Shaping the Future of Pharma](https://seqova.com/seqova-cross-border-pharma-partnerships/): In today’s pharma landscape, cross-border collaboration is no longer optional, it’s essential. From biotech startups seeking validation partners to established pharma companies sourcing innovation, SEQOVA cross-border pharma partnerships are reshaping how therapies move from lab to patient. At SEQOVA, we’ve made it our mission to bridge these worlds. Connecting innovation from Asia with opportunity in Europe and the U.S., and vice versa. China’s Rise as a Partner in Innovation In recent years, China has emerged as a powerhouse for biotech and pharmaceutical development. The scale of R&D investment, clinical data generation, and technical advancement has been remarkable. In 2025, Chinese biopharma […]
- [Mergers and Acquisitions in the Pharma Industry: A Strategic Imperative](https://seqova.com/mergers-and-acquisitions-in-the-pharma-industry-a-strategic-imperative/): Pharma M&A trends, key drivers, and top 2023–2024 deals A Structural Pillar of Pharma Strategy: Mergers and Acquisitions Mergers and acquisitions (M&A) have become a cornerstone strategy in the pharmaceutical industry, enabling companies to expand their product portfolios, enter new markets, and achieve cost efficiencies. As the industry faces mounting challenges such as patent expirations, regulatory hurdles, and the need for continuous innovation, M&A activities serve as a critical tool for maintaining competitive advantage and fostering long-term growth. The Importance of Mergers and Acquisitions in Pharma The pharmaceutical industry operates in a highly competitive and research-intensive environment. M&A activities offer several […]
- [Navigating the Complex Landscape of Drug Shortages: A Global Perspective, Including the Role of Innovative Solutions](https://seqova.com/navigating-the-complex-landscape-of-drug-shortages-a-global-perspective-including-the-role-of-innovative-solutions/): Uncover how drug shortages occur globally, their impacts and the potential solutions. Understanding Drug Shortages Drug shortages have become an increasingly concerning issue worldwide, impacting patients, healthcare providers, and healthcare systems. From life-saving medications to everyday prescriptions, the unavailability of essential drugs can have profound consequences. This article explores the complexities of drug shortages, examining their causes, impacts, the efforts being made to address this global challenge, and highlighting the role of companies like SEQOVA in bringing affordable drug supplies to market. What are Drug Shortages? A drug shortage occurs when the supply of a medication cannot meet the demand. This can […]
- [A Comprehensive Guide to Registering a Medicinal Product in the U.S.](https://seqova.com/a-comprehensive-guide-to-registering-a-medicinal-product-in-the-u-s/): Step-by-step guide to FDA drug registration with timelines, costs, and approval shortcuts Understanding Drug Classification Registering a medicinal product to market in the United States is a rigorous process governed by the Food and Drug Administration (FDA). Whether you are developing a new drug, a generic equivalent, a biologic, or an over-the-counter (OTC) medication, compliance with strict regulatory standards is essential. Understanding the classification of a medicinal product is the first crucial step before initiating the registration process. The FDA categorizes medicinal products into four main types: new drugs, generic drugs, biologics, and over-the-counter (OTC) drugs[1]. New drugs require full clinical […]
- [From Setup to Compliance: CSV That Delivers](https://seqova.com/csv-for-pharma-manufacturing/): Discover how SEQOVA supported a pharma manufacturer in achieving full system validation before production go-live. From MES and LIMS to ERP and SCADA, we delivered a structured CSV approach aligned with EU Annex 11—ensuring digital compliance from setup to sustained operations.
- [The Power of Market Reports in the Pharma Industry: Why They Matter](https://seqova.com/the-power-of-market-reports-in-the-pharma-industry/): Discover how market reports guide strategic decisions in pharma Market Reports: Intelligence for Decision Making In the fast-paced and highly competitive pharmaceutical industry, access to accurate and timely data is a game-changer. Whether you’re a global pharma giant, a biotech startup, or an investor looking for the next big opportunity, market reports serve as indispensable tools that provide clarity in a complex industry. These comprehensive documents analyze market trends, competition, growth opportunities, regulatory landscapes, and industry challenges. Their insights help businesses make informed strategic decisions, ensuring they stay ahead in a highly competitive environment.In this article, we will touch on what’s […]
- [The Rise of CDMOs: Transforming Pharmaceutical Outsourcing](https://seqova.com/the-rise-of-cdmos-transforming-pharmaceutical-outsourcing/): Discover the key advantages & global trends in CDMOs Introduction: CMO vs. CDMO – What’s the Difference? In the ever-evolving pharmaceutical industry, outsourcing has become a critical strategy for drug companies looking to streamline operations and accelerate time to market. Traditionally, pharmaceutical firms relied on Contract Manufacturing Organizations (CMOs) for large-scale drug production. However, as the industry shifts towards more complex therapies and personalized medicine, Contract Development and Manufacturing Organizations (CDMOs) have emerged as a more comprehensive solution. In this article, we will take a more in-depth look into the shift away from CMOs to the more preferred CDMOs and highlight […]
- [Navigating Marketing Authorisation Transfers (MATs): Strategies for Regulatory Compliance](https://seqova.com/navigating-marketing-authorisation-transfers-mats-strategies-for-regulatory-compliance/): Understanding the Scenario In a landmark transaction, two major multinational corporations (MNCs) agreed to transfer an extensive portfolio of over 10,000 MATs across multiple markets to a newly formed joint venture. Given the scale and complexity of the transfer, a well-structured approach was essential for seamless execution. SEQOVA played a key role in overseeing the project, providing end-to-end support from strategy development to execution. Our team worked closely with all stakeholders to navigate regulatory challenges, mitigate risks, and ensure a smooth transition of marketing authorizations. Strategy for Success A successful MAT execution requires a combination of regulatory expertise, operational efficiency, and […]
- [Basics of Registering a Medicinal Product in the EU](https://seqova.com/basics-of-registering-a-medicinal-product-in-the-eu/): Discover the nuances of registering your medicinal product in the EU. Medical Product Registration in the EU: “How is it done?” Registering a medicinal product in the European Union (EU) involves compliance with strict regulatory requirements to ensure safety, efficacy, and quality. The process is governed by the European Medicines Agency (EMA) and National Competent Authorities (NCAs), depending on the chosen registration pathway. Take a look at the key considerations for registering a medicinal product in the EU. Regulatory Pathways available in the EU: “What options do I have to register my product in the EU?” The EU is made up […]
- [Offshoring Regulatory Affairs Lifecycle Management for Efficiency](https://seqova.com/offshoring-of-reg-affairs-lifecycle-management-operations/): Learn how offshoring regulatory affairs lifecycle management can optimize efficiency and compliance. Explore cost-effective strategies and global best practices.
- [QMS Implementation: Ensure Compliance & Operational Efficiency](https://seqova.com/qms-implementation/): Explore effective Quality Management System (QMS) implementation strategies to enhance compliance, streamline processes, and reduce risks. Learn from our real-world case study.
- [Streamlining Serious Adverse Event Narratives for Clinical Study](https://seqova.com/streamlining-serious-adverse-event-narratives-for-clinical-study/): Case Brief Scenario Serious adverse event (SAE) reports are now generated directly from electronic data capture (EDC) systems. However, formal SAE reports still require investigative sites to generate narratives of the event. Updates to SAE reports can be fragmented, and even when cumulative, the end result can be disorganized. The responsibility then falls on the sponsor to generate a patient narrative for Investigator Brochures and Clinical Study Reports, typically handled by the sponsor’s medical monitor or pharmacovigilance physician. The strain on these resources is considerable, especially if done at the end of the study. Strategy Outcome To further enhance your clinical […]
- [Simplifying Literature Searches for DSUR](https://seqova.com/simplifying-literature-searches-for-dsur/): Discover how our approach simplifies literature searches for DSUR, saving time and improving accuracy in safety reporting through streamlined processes.
- [Generate Intuitive Patient Profiles in Real-Time for Enhanced Clinical Research](https://seqova.com/generate-intuitive-patient-profiles-in-real-time-for-enhanced-clinical-research/): Discover the possibility of generating intuitive and usable patient profiles in real-time, enhancing clinical research with seamless data integration for improved decision-making.

## Pages

- [Ventures](https://seqova.com/therapeutic-venture-opportunities/): SEQOVA doesn’t just advise. We lead and structure therapeutic venture opportunities, aligning the right assets, capabilities, and partners to create durable value across borders. From Insight to Investment: Leading the Next Wave of Therapeutic Opportunity SEQOVA Ventures is the natural extension of our strategic expertise. Our on-the-ground experience allows us to identify high-potential therapeutic assets early and bring together the right stakeholders, guiding opportunities from concept through execution and creating sustainable, real-world impact. Our Approach Selective Focus We engage where science, strategy, and execution readiness align. Partnership First Collaboration is central to our model. We connect assets with the right partners […]
- [Solutions](https://seqova.com/pharma-solutions/): Our SEQOVA Pharma Solutions provide global expertise to help biotech and pharma companies navigate complex cross-border opportunities. We turn strategic insights into actionable plans, guiding innovators through regulatory, operational, and commercial challenges to achieve sustainable growth and value. Our Approach to Pharma Solutions We deliver comprehensive solutions for innovators and investors seeking to expand globally. By combining deep regulatory knowledge, technical expertise, and a strong network across China, the EU, and the US, SEQOVA ensures that each project is structured for success. Why SEQOVA Pharma Solutions Our SEQOVA Pharma Solutions stand out because we go beyond advisory services. We bring together […]
- [Home](https://seqova.com/): Bridging Biotech Between China and the West We enable cross-border biotech partnerships, helping Chinese innovators reach global markets and Western innovators succeed in China. The Innovator’s Dilemma China is one of the fastest-growing biotech markets, offering breakthrough innovation at scale. Yet complex regulations, uncertain pathways, and global headwinds often slow or stall deals. Making successful cross-border biotech transactions challenging. Success requires more than a partner. It requires on-the-ground expertise. For Western biotechs, this means trusted local insight; for Chinese innovators, it means navigating FDA/EMA standards and connecting with the right global partners. At SEQOVA, we bridge both worlds, turning barriers into […]
- [Insights](https://seqova.com/biotech-insights/): SEQOVA Biotech Insights SEQOVA Biotech Insights provides carefully curated research and analysis to support cross-border strategy, licensing decisions, and long-term value creation in global pharma and biotech. Our insights offer actionable intelligence on scientific innovation, regulatory pathways, manufacturing and quality systems, market entry strategy, and operational execution. Each piece is designed to help innovators, investors, and partners make better decisions in complex, regulated environments, where strategy only matters if it can be executed. While we publish select insights throughout the year, each post reflects SEQOVA’s perspective on how innovation, regulation, and execution intersect to create value, highlighting opportunities that might otherwise […]
- [Home Archive](https://seqova.com/home/): Transforming Pharma & Biotech Challenges into Success. At SEQOVA, we don’t just provide solutions— we craft pathways. From regulatory compliance to global market entry, our expertise ensures that every challenge becomes an opportunity for sustainable growth and excellence. Speak To Us For Let Us Build Success Together Partnering with SEQOVA means you’re never navigating challenges alone. We’re here to support your growth every step of the way—empowering your team, streamlining processes, and driving measurable results. If you’re ready to elevate your business and achieve sustainable success, we’re ready to make it happen. Insights Subscribe to receive our industry insights

## Optional

- [Agent (MCP protocol)](websites-agents.hostinger.com/seqova.com/mcp)

[comment]: # (Generated by Hostinger Tools Plugin)